Advertisement
U.S. markets open in 7 hours 4 minutes
  • S&P Futures

    5,081.00
    0.00 (0.00%)
     
  • Dow Futures

    38,976.00
    -17.00 (-0.04%)
     
  • Nasdaq Futures

    17,914.25
    -1.00 (-0.01%)
     
  • Russell 2000 Futures

    2,049.50
    +6.10 (+0.30%)
     
  • Crude Oil

    78.39
    -0.15 (-0.19%)
     
  • Gold

    2,045.20
    +2.50 (+0.12%)
     
  • Silver

    22.74
    +0.10 (+0.44%)
     
  • EUR/USD

    1.0837
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    4.2740
    0.0000 (0.00%)
     
  • Vix

    13.84
    +0.41 (+3.05%)
     
  • GBP/USD

    1.2661
    +0.0001 (+0.01%)
     
  • USD/JPY

    149.7120
    -0.9210 (-0.61%)
     
  • Bitcoin USD

    62,845.18
    +5,386.68 (+9.37%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,624.98
    -58.04 (-0.76%)
     
  • Nikkei 225

    39,166.19
    -41.84 (-0.11%)
     

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide a Corporate Strategic Update

Conference Call to be Held on May 15, 2023

RANCHO CORDOVA, Calif., May 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 and provide a corporate strategic update on Monday, May 15, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.

To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts/.

A webcast replay will be available on ThermoGenesis' website for three months by visiting the Investor page of the Company's website at www.thermogenesis.com.

About ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this press release, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company, or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and in the future could affect, actual results to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to launch new products and grow our CDMO business, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet FDA regulated requirements governing the Company's products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, risks associated with expanding into the Company's planned CDMO business, uncertainty associated with the COVID-19 pandemic, and other risk factors listed from time to time in our reports with the Securities and Exchange Commission ("SEC"), including, in particular, those set forth in ThermoGenesis Holdings' Form 10-K for the year ended December 31, 2022.

Company Contact: 
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact: 
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-first-quarter-ended-march-31-2023-and-provide-a-corporate-strategic-update-301820562.html

SOURCE ThermoGenesis Holdings, Inc.

Advertisement